Artefenomel/ferroquine

Drug Profile

Artefenomel/ferroquine

Alternative Names: Ferroquine/artefenomel; Ferroquine/OZ439; OZ439 mesylate/ferroquine; OZ439/4-aminoquinoline

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Medicines for Malaria Venture
  • Developer Medicines for Malaria Venture; Sanofi
  • Class Adamantanes; Aminoquinolines; Antimalarials; Cyclohexanes; Ferrous compounds; Morpholines; Peroxides; Small molecules
  • Mechanism of Action Hemozoin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Falciparum malaria; Malaria

Most Recent Events

  • 17 Jul 2015 Sanofi plans a phase IIb trial for Falciparum malaria in Gabon (NCT02497612)
  • 01 Jul 2015 Phase-II clinical trials in Falciparum malaria (In adults, In children, In infants, In adolescents, In the elderly) in Gabon (PO) (NCT02497612)
  • 06 Feb 2014 Phase-II clinical trials in Malaria treatment in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top